Healthcare
Portfolio spotlight
Our Portfolio
Benchling is a life sciences R&D cloud platform helping the next generation of scientists make breakthrough discoveries faster than ever before.
Milestones
- 2012 → Founded
- 2019 → Partnered, Series C
Partner
Delfi is developing a revolutionary test for early detection of cancer using machine learning on DNA in the blood.
Milestones
- 2019 → Founded
- 2019 → Partnered, Seed
Partner
Encoded Therapeutics, a precision gene therapy company, is developing genomics-driven medicines that have the potential to transform the treatment paradigm for severe genetic disorders.
Milestones
- 2014 → Founded
- 2019 → Partnered, Series C
Partner
NASDAQ: GILD Gilead is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need.
Milestones
- 1987 → Founded
- 1987 → Incubated by Menlo Ventures
- 1992 → IPO; NASDAQ: GILD
Partner
H1's health data platform supports the end-to-end therapeutic development process of medical companies and healthcare systems.
Acquired by Amazon PillPack is a full-service pharmacy that delivers a better, simpler experience through convenient packaging, modern technology, and personalized service.
Milestones
- 2013 → Founded
- 2015 → Partnered, Series C
- 2018 → Acquired by Amazon
Partner
NASDAQ: PLRX Pliant Therapeutics is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Milestones
- 2015 → Founded
- 2018 → Partnered, Series B
- 2020 → IPO; NASDAQ: PLRX
Partner
NASDAQ: RXRX Recursion is discovering transformative new treatments by combining automation, machine learning, and the world’s largest biological image datasets.
Milestones
- 2013 → Founded
- 2017 → Partnered, Series B
- 2021 → IPO; NASDAQ: RXRX
Partner
Our perspective
Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.
Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.
Cancer remains one of the leading causes of death in the U.S. and worldwide.
In the face of a national emergency in child and adolescent mental health, urgent measures are needed to help those in need.
Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship
Across life sciences, a quality management system (QMS) is critical for both regulatory compliance and continuous product innovation.
Insurtech has been hot—at least seven venture-backed insurers will have gone public since the second half of 2020.
Opioid use disorder (OUD) is an epidemic that will define our generation. Roughly 90 million Americans use opioids and over 10 million misuse them.
The COVID-19 pandemic changed the world of benefits forever. Companies rethought the traditional office paradigm and re-evaluated the suite of benefits that provide a strong work experience for employees.
We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.
At Menlo, we believe the pace of innovation in new medicines will continue to accelerate, powered by the combination of advances in biology, advances in information technology, and even the lasting implications of the global pandemic.
Nearly half of U.S. adults—108 million people—have high blood pressure, which is the #1 controllable risk for both heart disease and stroke, the two leading worldwide causes of death.
As part of the 21st Century Cures Act, the White House established rules compelling payers and hospitals to make patient health data easily shareable by modern technology standards.
H1 is a unique healthcare data SaaS company with proprietary data, compelling initial applications, and potential to expand.
